Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity
Overview
Authors
Affiliations
Significance: We found that duloxetine has potent OCT2-inhibitory properties and can diminish excessive accumulation of oxaliplatin into DRG neurons. In addition, pre-treatment of mice with duloxetine prevented OIPN without significantly altering the plasma pharmacokinetics and antitumor properties of oxaliplatin. These results suggest that intentional inhibition of OCT2-mediated transport by duloxetine can be employed as a prevention strategy to ameliorate OIPN without compromising the effectiveness of oxaliplatin-based treatment.
Contribution and expression of renal drug transporters in renal cell carcinoma.
Zuo Y, Li T, Yang S, Chen X, Tao X, Dong D Front Pharmacol. 2025; 15:1466877.
PMID: 40034145 PMC: 11873565. DOI: 10.3389/fphar.2024.1466877.
Haynes J, Joshi A, Larue R, Eisenmann E, Govindarajan R Pharmaceutics. 2025; 16(12.
PMID: 39771570 PMC: 11677988. DOI: 10.3390/pharmaceutics16121592.
Vascular dysfunction is at the onset of oxaliplatin-induced peripheral neuropathy symptoms in mice.
Taib S, Durand J, Dehais V, Boulay A, Martin S, Blugeon C Life Sci Alliance. 2024; 8(2).
PMID: 39578077 PMC: 11584327. DOI: 10.26508/lsa.202402791.
Targeting dorsal root ganglia for chemotherapy-induced peripheral neuropathy: from bench to bedside.
Ege E, Briggi D, Vu P, Cheng J, Lin F, Xu J Ther Adv Neurol Disord. 2024; 17:17562864241252718.
PMID: 39318973 PMC: 11421407. DOI: 10.1177/17562864241252718.
Mansooralavi N, Khomula E, Levine J Mol Pain. 2023; 19:17448069231185694.
PMID: 37338165 PMC: 10288414. DOI: 10.1177/17448069231185694.